Globe Newswire03.05.18
Nu-Med Plus Inc., a medical device company which explores and develops medical applications of new disruptive technologies in the medical field, announced that Keith L. Merrell has become the full-time chief financial officer (CFO) and secretary/treasurer.
Merrell brings over 30 years of business and accounting experience while serving as CFO or controller of five companies both public and private, and correspondingly he has had numerous years of involvement with Securities and Exchange Commission reporting during his professional tenure. His business career also includes extensive experience in mergers and acquisitions.
“As NU-MED PLUS has continued to grow and expand our business the need for Mr. Merrell to become full time became extremely clear. 2018 will be a busy year for our company with the anticipated FDA 510K filing for our Hospital INO Unit and with the progression of our other disruptive products, Keith’s experience and involvement will be instrumental in our success,” said Jeff Robins, president and CEO of Nu-Med-Plus.
Nu-Med Plus Inc. is a medical device development company created to explore medical applications of newly developed technologies. Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. The emphasis for Salt Lake City, Utah-based Nu-Med Plus is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries.
Merrell brings over 30 years of business and accounting experience while serving as CFO or controller of five companies both public and private, and correspondingly he has had numerous years of involvement with Securities and Exchange Commission reporting during his professional tenure. His business career also includes extensive experience in mergers and acquisitions.
“As NU-MED PLUS has continued to grow and expand our business the need for Mr. Merrell to become full time became extremely clear. 2018 will be a busy year for our company with the anticipated FDA 510K filing for our Hospital INO Unit and with the progression of our other disruptive products, Keith’s experience and involvement will be instrumental in our success,” said Jeff Robins, president and CEO of Nu-Med-Plus.
Nu-Med Plus Inc. is a medical device development company created to explore medical applications of newly developed technologies. Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. The emphasis for Salt Lake City, Utah-based Nu-Med Plus is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries.
